Pharmicell Corrects Stock Option Grant: Reduction to 350,000 Shares After Cancellation for One Grantee

According to the correction report, the number of stock option grantees decreased by 1 from 10 to 9 (excluding executive director Jeong Hee-cheol).
The number of shares granted decreased by 30,000 from 380,000 to 350,000 shares.
Exercise price is calculated as the weighted average price for the period before the grant date; exercise period is within 3 years after 2 years of service from the general meeting resolution date.
Fair value of 5,566 won, closing price on grant date of 11,080 won, risk-free rate of 2.66%, expected volatility of 56.55%, and other valuation assumptions disclosed.